Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Natural Osimertinib Mesylate raw Materials Powder
Product Overview:
AZD9291(mesylate), or oxitinib mesylate, is indicated for disease progression during or after previous treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by testing with EGFRT790M mutation positive. AZD9291(mesylate) is highly selective, with an IC50 of 11.4nM and 12.9nM for T790M/L858R mutation and exon 19 deletion EGFR, respectively, and an inhibitor activity (IC50) of 494nM for wild-type EGFR. Ositinib is an irreversible inhibitor of EGFR and can form covalent bonds with molecular targets, so in theory the response lasts longer and the chance of resistance is correspondingly reduced
Natural Osimertinib Mesylate raw Materials Powder Attributes
CAS:1421373-66-1
MF:C29H37N7O5S
MW:595.72
EINECS:200-064-1
Specification: 99% min Osimertinib Mesylate Powder
Sample:Osimertinib Mesylate Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:White
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Natural Osimertinib Mesylate raw Materials Powder Details
Osimertinib Mesylate Powder Usage and Synthesis.
AZD-9291 mesylate is indicated for the treatment of patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR)T790M mutations or resistance to other EGFR inhibitors. The EGFR inhibitor, ocimotinib, must first be tested for T790M mutation before clinical use. Only patients with T790M mutations in non-small cell lung cancer can be targeted with ocimotinib.
Uses of Osimertinib Mesylate.
AZD-9291 mesylate is primarily used in the treatment of lung cancer, especially in patients with EGFR(epidermal growth factor receptor) mutation-positive non-small cell lung cancer. It selectively inhibits EGFR mutated proteins, and shows high selectivity and effectiveness against T790M secondary mutated EGFR, which has a good clinical application prospect.
Preparation of Osimertinib Mesylate.
With 4 - fluoro - 2 - methoxy - 5 - nitroaniline with 3 - (2 - chloro pyrimidine - 4 - base) - 1 - methyl indole reaction under the catalysis of monohydrate for N - (4 - fluoro - 2 - methoxy - 5 - nitrobenzene) - 4 - (1 - methyl - 1 h - indole - 3 -) pyrimidine - 2 - amine, after using N, N, N '- trimethyl ethylenediamine instead of fluorine, The nitro group was reduced with ferric ammonium and then reacted with 3-chloropropionyl chloride and then eliminated to obtain AZD9291 with a yield of 17.5%. AZD9291(mesylate) was prepared by salting AZD9291 with mesylate.
Product Method of Bulk Osimertinib Mesylate Powder.
